Banque Cantonale Vaudoise Buys Shares of 2,559 STERIS plc $STE

Banque Cantonale Vaudoise acquired a new position in shares of STERIS plc (NYSE:STE) in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 2,559 shares of the medical equipment provider’s stock, valued at approximately $566,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Nordea Investment Management AB boosted its stake in shares of STERIS by 259.0% in the fourth quarter. Nordea Investment Management AB now owns 51,602 shares of the medical equipment provider’s stock worth $13,165,000 after buying an additional 37,228 shares during the last quarter. Legal & General Group Plc lifted its position in shares of STERIS by 5.3% during the 3rd quarter. Legal & General Group Plc now owns 693,116 shares of the medical equipment provider’s stock valued at $171,505,000 after buying an additional 34,981 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of STERIS by 9.4% in the third quarter. Dimensional Fund Advisors LP now owns 1,039,351 shares of the medical equipment provider’s stock valued at $257,157,000 after purchasing an additional 89,250 shares during the period. Goldman Sachs Group Inc. boosted its holdings in STERIS by 40.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 633,530 shares of the medical equipment provider’s stock worth $160,613,000 after buying an additional 183,680 shares during the last quarter. Finally, Groupama Asset Managment purchased a new stake in shares of STERIS during the third quarter worth approximately $1,163,000. 94.69% of the stock is owned by hedge funds and other institutional investors.

STERIS Stock Performance

NYSE:STE opened at $215.59 on Monday. STERIS plc has a 52 week low of $195.14 and a 52 week high of $269.44. The company has a fifty day simple moving average of $212.77 and a two-hundred day simple moving average of $233.10. The company has a quick ratio of 1.54, a current ratio of 2.09 and a debt-to-equity ratio of 0.25. The company has a market cap of $21.01 billion, a price-to-earnings ratio of 27.19 and a beta of 0.93.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 EPS for the quarter, missing analysts’ consensus estimates of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The company had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period in the prior year, the firm posted $2.74 earnings per share. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. As a group, equities analysts anticipate that STERIS plc will post 11.18 earnings per share for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 26th. Shareholders of record on Monday, June 8th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 1.2%. The ex-dividend date of this dividend was Monday, June 8th. STERIS’s dividend payout ratio (DPR) is presently 31.78%.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 6th. KeyCorp reduced their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. Weiss Ratings cut STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $270.00 price objective on shares of STERIS in a research report on Thursday, May 21st. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Insiders Place Their Bets

In related news, CEO Daniel A. Carestio sold 3,054 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $214.64, for a total value of $655,510.56. Following the transaction, the chief executive officer owned 65,021 shares in the company, valued at $13,956,107.44. The trade was a 4.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $209.51, for a total value of $310,284.31. Following the sale, the director owned 38,964 shares of the company’s stock, valued at $8,163,347.64. This trade represents a 3.66% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 7,328 shares of company stock valued at $1,554,051. Insiders own 1.12% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.